A young man with acute dilated cardiomyopathy associated with methylphenidate
Author(s) -
Tor-Bjarne Nymark
Publication year - 2008
Publication title -
vascular health and risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.892
H-Index - 68
eISSN - 1178-2048
pISSN - 1176-6344
DOI - 10.2147/vhrm.s2410
Subject(s) - medicine , ejection fraction , ventricle , methylphenidate , cardiology , heart failure , dilated cardiomyopathy , dobutamine , cardiomyopathy , anesthesia , attention deficit hyperactivity disorder , hemodynamics , psychiatry
An 18-year-old obese man with a body mass index of 40, diagnosed with attention-deficit hyperactivity disorder and treated with methylphenidate (Concerta) was acutely admitted to hospital with hypoxia and dyspnoea. On investigation signs of liver-, renal-, and heart-failure were found. Noradrenalin infusion was started. Echocardiography showed dilated left ventricle and an ejection fraction (EF) of 25%. Liver function improved, noradrenalin and dobutamine were tapered, but three days after admission a new echocardiography showed an EF of 10%. The patient was transferred to the National Hospital (Rikshospitalet, Oslo), where intensified treatment including intra aortic balloon pump (IABP) was instituted. Cardiac function improved, and 3 weeks later the IABP was disconnected. EF at this point was 15%. The patient was denied heart transplantation due to various cofactors. The investigation concluded with a probable relationship between his cardiomyopathy and the use of methylphenidate (Concerta).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom